Angiogenesis is the growth of new blood vessels from ones that already exist. It happens throughout your life, from the healing of a paper cut to the monthly rebuilding of the uterine lining, and it is tightly controlled by a balance of signals that tell vessels when to grow and when to stop. When that balance tips the wrong way, the consequences range from blinding eye disease to cancer spreading to distant organs. Understanding how vessel growth works, and how medicine tries to dial it up or shut it down, touches some of the most active frontiers of modern biology.
How New Vessels Sprout
The process starts with a simple problem: cells somewhere in the body are not getting enough oxygen. Low oxygen triggers a molecular alarm. A protein called HIF-1α accumulates in oxygen-starved cells, where it switches on the gene for vascular endothelial growth factor, or VEGF, the single most important “grow new vessels” signal the body has.1Current Medicinal Chemistry. Critical Role of Hypoxia Sensor – HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing VEGF diffuses outward from the oxygen-starved area and reaches the lining cells of nearby blood vessels, the endothelium. That is where things get physical.
When VEGF reaches a vessel, one endothelial cell responds more strongly than its neighbors and becomes what researchers call a “tip cell.” This cell extends finger-like projections and begins migrating toward the VEGF source. The cells behind it, called stalk cells, proliferate and elongate to form the shaft of the new vessel. VEGF and another signaling pathway called Notch talk to each other constantly during this process, making sure only one cell takes the lead while the rest stay in line and multiply.2PubMed Central. VEGF and Notch in tip and stalk cell selection Without that coordination, you would get a disorganized mass of cells rather than a functional tube.
Before the tip cell can push forward, it has to chew through the tissue surrounding the parent vessel. Enzymes called matrix metalloproteinases break down the structural scaffolding around the vessel wall, clearing a path for the sprout to invade surrounding tissue.3Cardiovascular Research. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead These same enzymes help carve out a hollow center inside the growing sprout so blood can eventually flow through it. The body also produces natural inhibitors of these enzymes, called TIMPs, to keep the breakdown from going too far.4PubMed Central. Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Finishing the Job and Stabilizing a New Vessel
A freshly sprouted vessel is fragile. It is just a thin tube of endothelial cells with no structural support. To become a durable, functioning blood vessel, it needs to recruit support cells called pericytes, which wrap around the outside of the tube and give it strength. A family of signaling molecules called angiopoietins, working through receptors called Tie, governs this maturation step.5PubMed Central. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation Without proper pericyte coverage, vessels leak, collapse, or regress. This distinction between a raw sprout and a mature, stable vessel turns out to matter enormously in disease, as we will see with tumors.
The body also produces its own brakes. Endostatin, a small fragment snipped from a common structural protein called collagen XVIII, is one of the most potent natural inhibitors of angiogenesis.6PubMed Central. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications This brake-and-gas-pedal arrangement is central to the whole system: healthy angiogenesis depends on pro-growth signals like VEGF being balanced by anti-growth signals like endostatin. Shift the ratio either way and problems follow.
Where Angiogenesis Happens Normally
In adults, most blood vessels sit quietly and do not grow. Angiogenesis fires up in only a handful of normal situations, and wound healing is the most familiar. When you cut yourself, the clot that forms is initially devoid of blood supply. Within a couple of days, capillary sprouts invade the clot and organize into a network throughout the new tissue, delivering oxygen and nutrients that the healing site desperately needs.7PubMed. Angiogenesis in wound healing In animal studies, new capillary buds appear within about 72 hours, arising exclusively from small veins called venules, and over the next one to two weeks they form an elaborate interconnected network.8PubMed. Initiation and pattern of angiogenesis in wound healing in the rat This timing explains why deep wounds heal slowly and why anything that impairs blood vessel growth, such as diabetes or certain medications, slows healing dramatically.
The other major site of routine angiogenesis is the uterus. Every menstrual cycle, the uterine lining rebuilds itself, and that rebuilding requires an entirely new vascular bed. Estrogen and progesterone regulate VEGF production in the endometrial tissue, driving this monthly round of vessel growth and regression.9Biology of Reproduction. Effect of Estrogen on Vascular Endothelial Growth/Permeability Factor Expression by Glandular Epithelial and Stromal Cells in the Baboon Endometrium The fact that reproductive hormones directly control angiogenesis helps explain why certain gynecological conditions involving abnormal blood vessel growth, like endometriosis, are so closely tied to hormonal status.
Exercise and Vessel Growth in Muscle
Physical activity is one of the few things that reliably stimulates angiogenesis in healthy adult tissue. When you exercise regularly, the increased blood flow creates mechanical forces on the inner walls of your vessels. Endothelial cells sense this shear stress and launch signaling cascades that promote vascular health, including vessel remodeling and growth.10PubMed Central. Integrating molecular and cellular components of endothelial shear stress mechanotransduction Over several weeks of endurance training, capillary density in skeletal muscle measurably increases. Research has shown that as little as four to eight weeks of endurance exercise can boost capillary density, even in previously sedentary or obese individuals.11PubMed Central. The effect of different training modes on skeletal muscle microvascular density and endothelial enzymes controlling NO availability More capillaries per muscle fiber means better oxygen delivery, which is one of the reasons trained athletes extract oxygen from blood more efficiently than sedentary people.
When Angiogenesis Goes Wrong in Tumors
Cancer cells, like all cells, need oxygen and nutrients. A tiny cluster of cancer cells can survive by soaking up what diffuses from nearby vessels, but once a tumor grows beyond a millimeter or two, it hits a wall: without its own blood supply, it cannot keep expanding. The concept that tumors must recruit new blood vessels to grow was championed by surgeon Judah Folkman starting in the 1970s, and it took decades for the idea to gain mainstream acceptance.12PubMed Central. Judah Folkman, a pioneer in the study of angiogenesis Today it is a pillar of cancer biology.
The moment when a dormant tumor begins actively recruiting vessels is called the “angiogenic switch.” It happens when the tumor’s pro-growth signals, primarily VEGF, overwhelm the body’s anti-growth brakes.13PubMed. The angiogenic switch in carcinogenesis Once the switch flips, new vessels flood into the tumor, and growth accelerates. But tumor vessels are not normal vessels. The relentless, unbalanced flood of VEGF produces a vascular network that is chaotic: dilated, twisted, and leaky.14PubMed Central. Normalization of the vasculature for treatment of cancer and other diseases This abnormality has paradoxical consequences. The leaky vessels actually make it harder for chemotherapy drugs to reach tumor cells evenly, and the resulting uneven oxygen supply creates pockets of severe hypoxia inside the tumor, which in turn drives even more aggressive behavior from the cancer cells.
Anti-Angiogenic Cancer Therapy and Its Limits
If tumors need blood vessels to grow, then blocking vessel growth should starve the tumor. That reasoning led to the development of anti-angiogenic drugs, the most well-known being bevacizumab, which directly blocks VEGF.15PubMed Central. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy These drugs are now used against a range of cancers, often in combination with chemotherapy. The idea is not only to starve the tumor but also, counterintuitively, to temporarily “normalize” the chaotic tumor vessels so that chemotherapy can be delivered more evenly during a brief window when the vasculature becomes less leaky and more functional.
The results, though, have been mixed. Anti-angiogenic drugs extend survival in some cancers but rarely cure them, and resistance is common. One reason is a phenomenon called vascular co-option: instead of growing new vessels, tumor cells can hijack pre-existing blood vessels in the organs they invade. This sidestep is especially common in organs with dense existing vasculature, such as the brain, liver, and lungs, and it represents one of the main ways tumors resist anti-angiogenic therapy.16PubMed Central. Vascular co-option in resistance to anti-angiogenic therapy When a cancer cell wraps itself around a vessel that was already there, blocking new vessel growth does nothing. Researchers are now exploring ways to target co-option as well, but this remains an early-stage effort.
Angiogenesis in the Eye
The retina is one of the most metabolically demanding tissues in the body, and abnormal blood vessel growth there can be devastating. Two of the most common causes of blindness from retinal disease, diabetic retinopathy and the “wet” form of age-related macular degeneration, both involve new vessels growing where they should not. These rogue vessels leak fluid, cause swelling, and destroy the delicate architecture the retina needs for sharp vision.17PubMed Central. Treatment of neovascular age-related macular degeneration in patients with diabetes
Anti-VEGF therapy has been transformative here. Drugs injected directly into the eye block the growth signal driving those rogue vessels. For diabetic macular edema, anti-VEGF injections have shown significantly positive results for both visual acuity and the physical structure of the retina, and they are now a first-line treatment.18PubMed Central. Anti-VEGF for the Management of Diabetic Macular Edema Similar injections are the standard of care for wet macular degeneration. The catch is that these treatments require repeated injections, often monthly or bimonthly, and the treatment burden is substantial: missing appointments can mean losing vision. Still, anti-VEGF therapy in the eye is arguably the clearest clinical success story in the entire angiogenesis field. It works better here than in cancer, likely because the eye is a contained space where drugs can reach their target at high concentration, and because the abnormal vessels in the eye are more straightforwardly dependent on VEGF than tumor vessels are.
Promoting Angiogenesis for Heart and Limb Disease
Not every clinical situation calls for shutting angiogenesis down. In peripheral artery disease, where narrowed arteries starve the legs of blood flow, the goal is the opposite: get new vessels to grow and restore circulation. Therapeutic angiogenesis, the deliberate stimulation of new vessel growth, has been explored for over two decades in patients who have no surgical options for restoring blood flow. Approaches have included injecting genes for VEGF or other growth factors directly into the affected tissue, transplanting stem cells, and delivering growth factor proteins.19PubMed Central. Therapeutic angiogenesis-based strategy for peripheral artery disease Several strategies have reached clinical trials, but no approach has yet become a routine treatment. The biology turns out to be harder to control from the outside than researchers initially hoped: simply dumping VEGF into ischemic tissue tends to produce leaky, immature vessels rather than the stable, well-organized network the tissue actually needs. Ongoing work focuses on delivering multiple signals in sequence, mimicking the natural cascade of sprouting followed by maturation.
Lymphatic Vessels and Cancer Spread
Blood vessels are not the only plumbing system tumors can exploit. The lymphatic network, which drains fluid from tissues and plays a central role in immunity, can also grow new vessels in a parallel process called lymphangiogenesis. Two members of the VEGF family, VEGF-C and VEGF-D, drive lymphatic vessel growth rather than blood vessel growth, and some tumors produce large amounts of these molecules.20Cancer Cell. VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by Collecting Lymphatic Endothelial Cells
This matters because the lymphatic system is often the first highway cancer cells use to spread. Research in animal models has shown that VEGF-C not only promotes lymphatic growth at the primary tumor site but also expands the lymphatic network inside sentinel lymph nodes, essentially remodeling the highway system before the cancer cells even arrive.21PubMed Central. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites Once cancer cells reached those remodeled nodes, they were more likely to spread further to distant organs like the lungs. In a related finding, VEGF-D was shown to promote lymph node and lung metastasis in a pancreatic cancer model while actually suppressing blood vessel growth in the tumor itself, demonstrating that the two vascular systems can be regulated independently by the tumor.22The American Journal of Pathology. Vascular Endothelial Growth Factor-D Induces Lymphangiogenesis, Promotes Joint Lymph Node and Lung Metastasis, and Represses Angiogenesis in a Mouse Model of Pancreatic Beta-Cell Carcinogenesis This complexity explains why blocking VEGF-A alone, the target of most current anti-angiogenic cancer drugs, may leave the lymphatic metastatic route wide open.
Imaging Angiogenesis Without Surgery
Being able to see angiogenesis happening inside a living person, without cutting them open, would be enormously useful. Clinicians want to know whether a tumor is actively building new vessels, whether an anti-angiogenic drug is working, and how aggressively a cancer is behaving. Traditional imaging methods like CT and MRI can show vessel structure, but they cannot easily tell you whether new vessel growth is actively underway at a molecular level.
One promising approach targets a protein on endothelial cells called integrin αvβ3, which is expressed at high levels on the surface of cells that are actively participating in angiogenesis but largely absent from resting vessels. Researchers developed a radioactive tracer, called [18F]Galacto-RGD, that binds specifically to this integrin and can be detected by PET scanning. In cancer patients, PET imaging with this tracer showed that it could distinguish tumors with high levels of active vessel growth from those with lower angiogenic activity, providing a noninvasive snapshot of how vascularized the tumor was at a molecular level.23PLoS Medicine. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD Because integrin αvβ3 expression has been established as a surrogate marker of angiogenic activity, imaging it could serve as an early indicator of whether anti-angiogenic therapy is working at the molecular level, potentially weeks before conventional scans show a change in tumor size.24PubMed Central. Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
This kind of molecular imaging is still largely a research tool rather than a routine clinical test, but it represents a shift in how oncologists might eventually monitor treatment. Instead of waiting months to see whether a tumor shrank on a CT scan, a clinician could potentially check within days whether the drug is actually doing what it is supposed to do at the vessel level. That speed matters when the alternative is spending weeks on an ineffective drug while the cancer continues to progress.
Why Tumors Are Not the Only Disease Where This Matters
The reach of angiogenesis-related disease extends well beyond cancer and eyes. Psoriasis involves excessive blood vessel growth in the skin. Rheumatoid arthritis features aggressive angiogenesis in the lining of inflamed joints, feeding the cycle of tissue destruction. Obesity involves expansion of fat tissue, which requires new vessels to sustain it. Even Alzheimer’s disease has been linked to changes in the brain’s microvasculature, though whether those changes are a cause or consequence remains debated. The flip side is equally broad: conditions like chronic non-healing wounds, peripheral artery disease, and tissue damage after heart attacks all involve insufficient angiogenesis. This duality, too much vessel growth in some diseases and too little in others, is what makes the field so therapeutically versatile and so biologically challenging.
One of the hardest problems in the field is precision. Anti-VEGF therapy in the eye blocks vessel growth locally and effectively. The same class of drug given systemically for cancer blocks vessel growth everywhere, which is why side effects like high blood pressure, impaired wound healing, and kidney protein leakage are common. And therapeutic angiogenesis for ischemic limbs struggles because delivering a growth factor to one area without accidentally feeding vessel growth somewhere unwanted is difficult. The fundamental biology is the same in all these contexts. The engineering challenge of controlling it with spatial and temporal precision in a living person is what separates a laboratory insight from a reliable treatment.